-
Pipeline Update
Pfizer reported on its biotherapeutics research and development pipeline on January 27, 2010. The updated pipeline showed 133 programs in Phase I through registration and included:
- 30 compounds in development for various oncology indications;
- 10 compounds in development for Alzheimer's disease;
- Eight compounds in development for pain;
- 11 compounds in development for inflammation; and
- 27 biologics and six vaccines.
Late-stage compounds in development include our novel JAK-3 inhibitor for rheumatoid arthritis; tanezumab for osteoarthritis of the knee; PF-02341066 for advanced small-cell lung cancer; and apixaban, an investigational blood thinner for acute coronary syndrome, being developed with Bristol-Myers Squibb.
-
Prioritizing the Pipeline
Pfizer has identified six "Invest to Win" areas of research that hold significant potential opportunities for innovation and leadership: oncology, pain, inflammation, Alzheimer's disease, psychoses and diabetes. Pfizer's pipeline, streamlined following the acquisition of Wyeth, demonstrates focused investment in these areas of great unmet medical need, as well as growth in the critical technologies of vaccines and biologics. Approximately 70 percent of Pfizer's research projects and 75 percent of the late-stage portfolio are now focused on these areas.
-
Prevnar 13 Approved in More Than 40 Countries
Pneumococcal disease is one of the world's leading causes of vaccine-preventable death worldwide for children younger than 5 years old. Pfizer's Prevnar 13 (known as Prevenar 13 in most markets outside the U.S.) is approved for the prevention of serious pneumococcal disease in infants and young children. Pfizer is also in the late stages of investigating the use of Prevnar 13 to protect older adults, who are also at increased risk of developing invasive pneumococcal disease. This vaccine includes the seven serotypes in Prevnar, plus an additional six serotypes, including serotype 19A, now the most common cause of invasive pneumococcal disease among children in the U.S. under 5 and increasing in prevalence elsewhere. On March 23, 2010, Pfizer announced a 10-year Provisional Supply Agreement to supply Prevenar 13 for infants and young children in the world's poorest countries, under the terms of the Advance Market Commitment (AMC) pilot project against pneumococcal disease. The AMC procurement process is designed to provide the poorest nations greater access to new pneumoccal conjugate vaccines. The agreement is subject to prequalification by the World Health Organization and AMC eligibility designation, which are both expected later this year. This process is administered by the United Nations Children's Fund, piloted by the GAVI Alliance and funded by the Bill & Melinda Gates Foundation and the governments of Italy, the U.K., Canada, Russia and Norway. (Read more at www.pfizer.com/news.)
-
ViiV Healthcare Launches to Combat HIV
In 2009, Pfizer and GlaxoSmithKline (GSK) launched a new company, ViiV Healthcare, dedicated to delivering advances in HIV treatment and care. This new company, focused solely on research, development and commercialization of HIV treatments, opens a new opportunity to advance the work against HIV worldwide by combining the work of two companies known for innovation in HIV treatment. ViiV Healthcare integrates the pipeline and marketed HIV portfolios of both Pfizer and GSK, and will continue the commitments of these two companies to improve access to HIV medicines for everyone. Not-for-profit pricing for HIV medicines continues for those countries most in need. ViiV Healthcare is also supporting research and development activities specifically to address access to HIV medicines in the developing world, including treatments and formulations for children living with HIV, and managing a new fund to help prevent mother-to-child transmission.
In Our Pipeline